Research
Hormonal
Newer GLP-1 receptor agonists (semaglutide) and dual agonists (tirzepatide) significantly outperform older medications and lifestyle interventions alone, achieving weight losses of 12-17%.
Newer injectable medications like semaglutide (2.4mg weekly) and tirzepatide are significantly more effective than older drugs, achieving 12-17% weight loss. They represent a major step forward in pharmacotherapy for obesity.
GoodSupportsHIGH confidence
Two new medications that are under investigation, semaglutide and tirzepatide, significantly improve on this... individuals receiving semaglutide... lost 17.4% from baseline... tirzepatide... produced a mean weight loss of -12% at 26 weeks at a dose of 15 mg per day.
Why this rating
Based on phase 2/3 trials and press releases; some data not yet in peer-reviewed journals at time of publication.
Source
Evidence‐based weight loss interventions: Individualized treatment options to maximize patient outcomes
George A. Bray et al. · Diabetes Obesity and Metabolism · 2020
DOI 10.1111/dom.14200
narrative_reviewCited 133×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- A modest weight loss of 5% to 10% produces significant improvements in glycaemia, blood pressure, and lipid profiles, whereas larger losses (15%+) are required for remission of type 2 diabetes and improvements in obstructive sleep apnea.Strong
- Low carbohydrate diets are not significantly superior to low fat diets for weight loss when protein content is held constant.Strong
- Bariatric surgery (specifically Roux-en-Y gastric bypass) produces the largest and most durable weight loss among current treatments, serving as a benchmark for efficacy, though individual response varies significantly.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →